A HIGH-TECH medicine manufacturer is set to create 50 new jobs while safeguarding more than 130 existing positions with the purchase of new premises in Stirling.
Symbiosis Pharmaceutical Services Ltd (Symbiosis), has recently announced the purchase of new premises, the Bruce Building in Castle Business Park.
The building is located close to Symbiosis’ existing manufacturing cleanrooms, testing laboratories and GMP Warehouse facilities. The new manufacturing capacity is hoped to safeguard more than 130 skilled life sciences jobs at Symbiosis and generate an additional 50 new jobs
READ MORE: Diageo plans to 'demolish' Scottish island's oldest whisky distillery
The facility fit-out project will be implemented over a three-year period with financial support provided by Barclays Bank for the purchase of the building.
The new manufacturing facility also includes plans for two new cleanroom-based production lines with the aim to strengthen the company's ability to support its biotechnology and pharmaceutical clients worldwide and the new medicines and therapies being developed.
Symbiosis CEO Colin MacKay commented: “By investing £1.75m ($2.25m) in the purchase of a 20,000sq/ft building and subsequently equipping it to provide additional world-class sterile manufacturing capacity for our existing and future clients globally represents the next major strategic chapter in the successful and consistently fast-growing trajectory of Symbiosis.
“This step-change in operational capacity, while retaining the organisational and cultural strengths of a fantastic team here at Symbiosis, positions the company for sustained growth and to bring continued added value to both clients and shareholders alike."
READ MORE: Ipso bins complaint from Michelle Mone's husband on Daily Mail story
Retiring Stirling Council Leader, councillor Chris Kane welcomed the "absolutely fantastic news for Stirling, the wider region and Scotland".
He added: “Symbiosis’ significant investment at their site will safeguard and create skilled jobs in Stirling’s thriving life sciences and manufacturing sector. It’s an endorsement of Stirling’s world-class talent, research skills and innovation, and our location at the heart of one of Europe’s largest and most well-connected biotech clusters.
“The announcement reaffirms Stirling’s reputation as a place for attracting and retaining businesses, and we look forward to working with high-growth, internationally-acclaimed businesses like Symbiosis to continue developing this key sector.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereLast Updated:
Report this comment Cancel